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Abstract 
Research indicates that sex differences are observed in the incidence of anxiety 
disorders, with females more likely to have an anxiety disorder than males. Animal 
and human studies suggest that gonadol hormones may influence the rate of 
extinction learning. In particular, studies have indicated that low oestrogen levels in 
females may impair extinction recall. The aim of the current study was to replicate 
the findings obtained by previous authors, by investigating sex differences in fear 
conditioning, fear extinction, and extinction recall, in particular in women with low 
levels of oestrogen. It was hypothesised that women with low oestrogen would 
display impaired fear extinction and extinction recall, in comparison to men, which 
was measured by skin conductance responses (SCR). Twenty-seven participants 
(fifteen females; twelve males) underwent a differential fear conditioning and fear 
extinction paradigm. Results revealed no sex differences in fear acquisition or late 
extinction. However, males displayed greater SCR to the CS- in early extinction, 
which may reflect greater arousal to uncertainty. Contrary to predictions, no 
significant sex differences were observed in the early recall phase. However, females 
displayed a trend for greater SCR responses during late recall, relative to men. These 
findings provide some support that females with low oestrogen display poorer fear 
extinction retention, compared to men. In addition, the findings suggest that males 
display enhanced responses to safety signals during extinction. It is possible that 
oestrogen may be an important factor in consolidating extinction memories, but 
further research is required to determine the role of oestrogen in facilitating 
extinction recall.  
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An inability to successfully extinguish a conditioned fear may contribute to 
the occurrence and maintenance of anxiety disorders (Milad et al., 2006). 
Epidemiological studies suggest that women have a greater propensity to develop an 
anxiety disorder than men (Kessler et al., 2005; Lebron-Milad & Milad, 2012; Merz 
et al., 2012). For example, studies have found that women are more likely to receive 
a diagnosis of posttraumatic stress disorder (PTSD), have greater severity of PTSD 
symptoms with a longer duration, and higher ratings of functional impairment 
(Cover, Maeng, Lebron-Milad, & Milad, 2014). In addition, 60% of individuals who 
have a diagnosis of generalised anxiety disorders are women, and these women are 
more likely to have a comorbid psychological disorder (Cover et al., 2014). Clinical 
research has indicated that sex hormones may play a role in influencing mood in 
women (Solomon & Herman, 2009). For example, hormonal fluctuations that often 
occur during premenstrual, postpartum and perimenopausal periods have been linked 
with higher incidences of depression and anxiety (Douma, Husband, O'Donnell, 
Barwin, & Woodend, 2005; Solomon & Herman, 2009). Recently there has been 
convergent animal and human evidence suggesting that low oestrogen levels are 
associated with impaired fear extinction learning, leading to suggestions that 
fluctuating levels of oestrogen may be a risk factor in developing anxiety disorders 
in women (Graham & Milad, 2013; Milad et al., 2006; Milad et al., 2010). However, 
the link between low levels of oestrogen and impaired fear extinction has originated 
primarily from the same researchers and this finding requires independent replication 
from a separate laboratory. Therefore, the aim of this project is to replicate the 
findings that low oestrogen is associated with impaired fear extinction and extinction 
recall. 
Fear Conditioning and Extinction Paradigms 
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Past research examining fear extinction has employed a differential fear 
conditioning and fear extinction paradigm (Chang et al., 2009; Graham & Milad, 
2011; Milad et al., 2006; Orr et al., 2000). In Day 1 of this paradigm, in the fear 
conditioning phase, participants are presented with a neutral conditioned stimulus 
(CS+), such as a coloured circle, that is paired with an aversive unconditioned 
stimulus (US), such as a mild shock, which elicits an unconditioned fear response 
(UR) (see Figure 1 below). A different coloured circle (CS-) is presented randomly 
interspersed with the CS+, and is never paired with the US and therefore acts as a 
safety signal.  
 
Figure 1. Example of a fear conditioning and fear extinction paradigm. 
 
After repeated pairings of the CS+ and US, the participant learns that the 
CS+ is predictive of the US, and this elicits a conditioned fear response (CR), 
typically reflected in increased skin conductance responses (SCR). In the fear 
extinction phase, the CS+ is repeatedly presented without the US, and this reduces 
and extinguishes the CR (see Figure 2). 
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Figure 2. Example of SCR in the habituation, acquisition, and extinction phase in a 
fear conditioning and fear extinction paradigm. 
 
 In Day 2 of the paradigm (extinction recall), which is identical to the 
extinction phase, the CS+ and CS- are presented in a random order with no US (see 
Figure 3 below). In the extinction recall phase, a greater conditioned response to the 
CS+ reflects poorer extinction retention. 
 
Figure 3. Example of the extinction recall phase.  
 
Past research examining fear conditioning and fear extinction has found a 
consistent pattern in fear responses, such that during the acquisition phase, fear 
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responses to a CS+ will increase, and during the extinction phase, the conditioned 
fear responses to a CS+ will decrease (Hermans, Craske, Mineka, & Lovibond, 
2006; Orr et al., 2000; Phelps, Delgado, Nearing, & LeDoux, 2004; Vansteenwegen 
et al., 2005). In humans, one of the most common measures of fear response is skin 
conductance. Using a differential fear conditioning and fear extinction paradigm, 
studies have shown increased skin conductance responses (SCR) during the 
acquisition phase, where a CS+ is paired with a US (Orr et al., 2000; Phelps et al., 
2004; Vansteenwegen et al., 2005). This pattern is not observed with the CS-. In the 
extinction phase, after repeated pairings of the CS+ without a US, SCR diminishes 
(Orr et al., 2000; Phelps et al., 2004; Vansteenwegen et al., 2005). Similar responses 
are observed in rats, with increases in the rat’s freezing or startle response in the 
acquisition phase, and reduction in the freezing or startle response in the extinction 
phase (Milad & Quirk, 2002; Walker, Ressler, Lu, & Davis, 2002). 
Sex Differences in Fear Conditioning and Extinction 
Inconsistent findings have been found in early studies of sex differences in 
fear conditioning and fear extinction (Andreano & Cahill, 2009; Jackson, Payne, 
Nadel, & Jacobs, 2006). However, those studies did not control for menstrual phases 
in female participants. Recent evidence indicates that there are sex differences in fear 
extinction that may be mediated by hormones, specifically oestrogen levels in 
women (Graham & Milad, 2013; Lebron-Milad, Graham, & Milad, 2012; Lebron-
Milad & Milad, 2012).  
Women in the different phases of the menstrual cycle have varying levels of 
oestrogen and progesterone (see Figure 4), which may have direct implications on 
rates of extinction learning (Farage, Osborn, & MacLean, 2008). In the early 
follicular phase (days 1-7 of the menstrual cycle), women typically have low levels 
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of oestrogen and progesterone, whereas women in the late follicular phase (days 8-
14) have elevated levels of oestrogen and low levels of progesterone (Lebron-Milad, 
Abbs, et al., 2012; Milad et al., 2006; Poromaa & Gingnell, 2014). In the luteal 
phase (days 15-28), women display elevated levels of oestrogen and progesterone 
(Fehring, Schneider, & Raviele, 2006). 
 
 
Figure 4. Oestrogen and progesterone levels in humans and rats across different 
phases of the menstrual cycle. 
 
Animal Evidence of Sex Differences in Fear Conditioning and Fear Extinction 
In an earlier study conducted by Chang et al. (2009), male rats, normally 
cycling female rats and ovariectomised female rats underwent a contextual fear 
conditioning and fear extinction paradigm. Chang et al. (2009) found that male rats 
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displayed greater levels of freezing following the contextual fear conditioning, 
relative to normally cycling female rats. Female rats in the proestrus phase, which is 
characterised by high levels of oestrogen (see Figure 4), and rats in the estrus phase, 
characterised by mid-levels of oestrogen, demonstrated greater extinction learning 
relative to male rats (Chang et al., 2009). This suggests that oestrogen may play an 
important role in mediating differences between male and female extinction learning. 
In addition, ovariectomised female rats that were injected with oestrogen exhibited 
greater extinction learning, which provides further evidence to support this idea 
(Chang et al., 2009). 
Using a 3-day fear conditioning and extinction paradigm, male and female 
rats received fear conditioning on Day 1, fear extinction on Day 2, and were tested 
their extinction recall on Day 3 (Milad, Igoe, Lebron-Milad, & Novales, 2009). Rats 
were tested in two phases of the estrous cycle: the proestrus phase (characterised by 
high levels of oestrogen and progesterone) and the metestrus phase (characterised by 
low levels of oestrogen and progesterone). There were differences obtained in the 
different groups of female rats in the extinction phase in the fear conditioning and 
fear extinction paradigm (Milad et al., 2009). Rats in the proestrus phase, relative to 
the metestrus phase displayed lower levels of fear behaviour, such as freezing, in the 
extinction recall task, which suggests a greater facilitation of extinction memory in 
the high oestrogen/progesterone phase (Milad et al., 2009). Female rats in the 
proestrus phase displayed similar levels of extinction recall to male rats (Milad et al., 
2009). 
In addition, Milad et al. (2009) compared the effect of the administration of 
oestrogen, progesterone, both oestrogen and progesterone, or vehicle in female rats 
in the metestrus phase (low levels of oestrogen), on fear conditioning and fear 
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extinction. The extinction recall task demonstrated that rats that were administered 
the vehicle exhibited higher amounts of freezing, relative to the other three groups 
(Milad et al., 2009). This lends further support to the idea that oestrogen has a 
possible role in the facilitation of extinction recall.  
 Furthermore, in an experiment conducted by Zeidan et al. (2011), naturally 
cycling rats in the metestrus phase (characterised by low oestrogen and 
progesterone) underwent a 3-day conditioning, extinction, and extinction recall 
paradigm, to examine the effect of having an immediate or a delayed administration 
of oestrogen after the extinction phase on Day 2 on the extinction recall phase on 
Day 3. Rats that were administered oestrogen after the extinction phase displayed 
lower levels of freezing in the recall phase, relative to rats that received vehicle 
(Zeidan et al., 2011). However, there was no difference between the recall phase in 
rats that were administered oestrogen or vehicle four hours after the extinction phase 
(Zeidan et al., 2011). 
Human Evidence of Sex Differences in Fear Conditioning and Fear Extinction 
In an early study conducted by Milad et al. (2006), a 2 day differential fear 
conditioning and extinction paradigm was used to examine the effect of sex and 
menstrual cycle in healthy humans. Specifically, they examined females in the early 
follicular phase of their menstrual cycle (characterised by low levels of oestrogen), 
and females in the late follicular phase of their menstrual cycle (characterised by 
high levels of oestrogen). On the first day, participants were presented with the fear 
conditioning and fear extinction procedure; on the second day, participants were 
tested on their extinction recall and fear renewal. A 500ms electrical stimulus was 
used as the US, which was delivered following the presentation of the CS+ in the 
fear conditioning procedure (100% reinforcement rate). Milad et al. (2006) found 
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that men displayed greater fear conditioning responses, exhibited as higher levels of 
skin conductance responses, relative to both groups of females. Contrary to 
predictions, women in the early follicular phase demonstrated lower SCR to the CS+ 
at recall, reflecting greater extinction retention, in comparison to women in the late 
follicular phase (Milad et al., 2006). There was no significant difference in extinction 
retention in women in the early follicular phase and men (Milad et al., 2006). 
However, it should be noted that the level of gonadol hormones in participants were 
not measured in this study. 
In a later study conducted by Milad et al. (2010), the differential fear 
conditioning and fear extinction paradigm was once again implemented, 
investigating the effect of oestrogen and sex differences, in healthy humans. 
However, in this study, women were divided into high and low oestrogen groups 
using a median split, rather than comparing women on the basis of their phase in 
their natural menstrual cycle (Milad et al., 2010). Men demonstrated higher levels of 
skin conductance responses in the acquisition phase, which supports the findings of 
Milad et al. (2006). In addition, Milad et al. (2010) found that women with low 
levels of oestrogen displayed a lower level of extinction retention (more fear), 
relative to men and women with high levels of oestrogen. It is possible that 
oestrogen may assist in the consolidation of extinction learning, as women with high 
oestrogen levels exhibit higher levels of extinction memory (Milad et al., 2010). This 
contradicts the findings of Milad et al. (2006), in which women in the early follicular 
phase exhibited less SCR to the CS+ at recall. Milad et al. (2010) suggest that the 
difference in results may be explained by the fact that they had measured the level of 
gonadal hormones in this study, whereas this was not examined in the study 
conducted by Milad et al. (2006). 
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In a study conducted by Zeidan et al. (2011), female participants were 
separated into high vs low oestrogen groups, and a 2-day fear conditioning and fear 
extinction paradigm that was identical to previous studies was used to examine the 
effect of oestrogen on fear extinction. This study showed that female participants 
with low levels of oestrogen, in comparison to females with high levels of oestrogen, 
showed higher levels of SCR at extinction recall, reflecting impaired extinction 
recall (Zeidan et al., 2011). This supports the findings of Milad et al. (2010), and 
also lends support to the idea that low levels of oestrogen in females may impair the 
retention of extinction memory. 
Additionally, a recent study conducted by Graham and Milad (2013) 
examined the impact of hormonal contraceptives and oestrogen supplementation on 
fear extinction recall in women. Research has indicated that combined hormonal 
contraceptives lead to a reduction in the level of oestrogen in females, leading to a 
level of oestrogen that is similar to the level of oestrogen exhibited in females in the 
early follicular phase (Pluchino et al., 2009). Graham and Milad (2013) found that 
women with low levels of oestrogen and women on hormonal contraceptives 
displayed greater SCR at extinction recall, relative to women with high levels of 
oestrogen. Additionally, Graham and Milad (2013) administered oestradiol to 
women in the low follicular phase 30 minutes prior to extinction training and found 
that they displayed lower levels of SCR (less fear) at extinction recall, relative to 
women in the early follicular phase who received placebo. This supports the findings 
obtained in rat studies, whereby rats that received an administration of oestrogen did 
not display impairments in extinction recall, compared to control (Graham & Milad, 
2013). This provides further evidence for the idea that low oestrogen may impair the 
consolidation of fear extinction at extinction recall.  
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The Current Study 
 Research has demonstrated that sex differences are observed in the incidence 
of anxiety disorders, with females being more likely than males to have an anxiety 
disorder (Kessler et al., 2005; Lebron-Milad, Abbs, et al., 2012). Despite these 
differences, limited studies have specifically examined the sex differences in fear 
conditioning and fear extinction, which is the process believed to underlie the 
development and treatment of anxiety disorders. The limited research suggests that 
oestrogen may play an important role in influencing the degree of fear extinction and 
retention of extinction memory (Graham & Milad, 2013; Milad et al., 2010; Zeidan 
et al., 2011). In particular, studies suggest that low levels of oestrogen may impair 
the retention of extinction memory, as female rats and female humans with low 
levels of oestrogen exhibit greater fear responses at extinction recall, relative to 
female rats and females humans with high levels of oestrogen, and male rats and 
male humans (Graham & Milad, 2013; Milad et al., 2009; Zeidan et al., 2011). 
Furthermore, when rats or humans with low levels of oestrogen are administered 
oestrogen prior to extinction training, they are able to increase their ability to retain 
their extinction memories (Graham & Milad, 2013; Milad et al., 2009; Zeidan et al., 
2011). Thus, oestrogen may be an important mediator of extinction memories. 
However, it should be noted that there have only been a limited number of studies 
examining these sex differences in fear extinction, which are also conducted by the 
same authors. Therefore independent replication of these findings are important as 
these findings may have potentially important clinical implications. 
Therefore, the primary aim is to examine differences in the rate of fear 
extinction learning between males and females in the early follicular phase by 
employing a fear conditioning and fear extinction paradigm. A secondary aim of the 
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current study is to examine sex differences in delayed extinction recall, as 
preliminary studies have found the effects of oestrogen predominantly in extinction 
recall rather than extinction learning. 
It is hypothesised that women in the early follicular phase (associated with 
low levels of oestrogen and progesterone) of their menstrual cycle will display 
impaired fear extinction, in comparison to men. This will be demonstrated in higher 
levels of SCR amplitude during the extinction phase to the CS+. It is also 
hypothesised that in the recall phase, women in the early follicular phase will display 
impaired fear extinction retention, relative to men. This will be indicated by a greater 
recovery of fear in females (indexed by greater SCR to CS+ at recall), relative to 
men. 
Method 
Participants 
Twenty-seven participants were recruited for the study from Psychology 1 
and students received course credit for their participation. Fifteen participants were 
women who were in the early follicular phase of their menstrual cycle (determined 
as being between days 2-7 of their menstrual cycle (n = 8), or in the sugar pill week 
of their contraceptive pill (n = 7), as research has shown similar levels of oestrogen 
as normally cycling women in the early follicular phase (Pluchino et al., 2009))1, and 
twelve participants were male. Salivary measures were used to measure oestrogen 
and progesterone levels and confirm menstrual phase position. All participants 
ranged from 18 to 45 years of age to control for menopause. Participants were 
excluded if they were taking hormonal contraceptives other than the contraceptive 
                                                        
1 Although recruitment focused on women not on contraceptives, due to considerable 
difficulty recruiting such participants, we needed to include women on 
contraceptives, but only while they were on the sugar pill phase. 
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pill, other medications, were pregnant, or if they reported hypertension or any 
psychological, neurological, or cardiovascular disorders. Participants refrained from 
alcohol consumption, illicit drug use and excessive exercise 24 hours prior to 
participation in the experiment. In addition, participants refrained from drinking 
caffeine or smoking three hours prior to the experiment, and refrained from eating 
one hour prior to the experiment. 
Design 
For the fear acquisition and extinction study, a 2 (Group: male, early 
follicular women) x 2 (CS type: CS+, CS-) x 4 (Trial: 1, 2, 3, 4) mixed factorial 
design was employed for the Habituation phase. A 2 (Group: male, early follicular 
women) x 2 (CS type: CS+, CS-) x 5 (Trial: 1, 2, 3, 4, 5) mixed factorial design was 
employed for the Acquisition, Early-Extinction, and Late-Extinction phase in 
Session 1. The dependent variable in Session 1 comprised SCR amplitude. In 
accordance with previous literature, a percent recovery of fear value was calculated 
to index extinction recall in Session 2 (Graham & Milad, 2013).  
Materials 
Fear conditioning and extinction paradigm. The current study used a 
differential fear conditioning and extinction paradigm adapted from previous studies 
(Inslicht et al., 2013; Milad et al., 2006; Zeidan et al., 2011). The CS+ and CS- 
comprised a blue or red circle, with colours counterbalanced between participants. 
The US was a 500-ms mild electric shock produced by the Powerlab 16/35 Stimulus 
Isolator, and was delivered to the dominant hand by the Powerlab 16/35 Recording 
Bare Electrode. Skin conductance response amplitude was measured through the use 
of the PowerLab 16/35 GSR Amp and the GSR Finger Electrodes, which was 
attached to the non-dominant hand on the first and third fingers. The differential fear 
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conditioning extinction paradigm was presented using Inquisit 3.0.6.0 and Labchart 
7.3.7 was used to obtain skin conductance response amplitude. 
Saliva samples. Salivary samples were obtained using Salimetrics assay kits 
and analysed for oestrogen and progesterone level via commercially available 
standardised techniques in the pathology laboratory at Macquarie University, and to 
confirm the early follicular phase in women2. 
Depression, Anxiety and Stress. The Depression Anxiety Stress Scales 
(DASS-21; (Lovibond & Lovibond, 1995)) is a 21-item scale (see Appendix A1) that 
was administered to rate mood over the past week. The DASS-21 uses a 4-point 
Likert scale in response to statements such as “I found it hard to wind down”, 
ranging from 0 (did not apply to me at all) to 3 (applied to me very much, or most of 
the time). The DASS-21 displayed high internal consistency in the depression, 
anxiety and stress subscales, with Cronbach’s alphas of .94, .87 and .91 in each scale 
respectively (Antony, Bieling, Cox, Enns, & Swinson, 1998). 
Emotion Dysregulation. The Difficulties in Emotion Regulation Scale 
(DERS; (Gratz & Roemer, 2004)) is a 36-item questionnaire (see Appendix A2) was 
used to assess emotion dysregulation, using a 5-point scale with 1 being ‘almost 
never’ and 5 being ‘almost always’. An example included “When I’m upset, I feel 
guilty for feeling that way”. The DERS demonstrated high internal consistency with 
a Cronbach’s alpha of .93 (Gratz & Roemer, 2004).  
Health Questionnaire. A health questionnaire was used to assess 
medication, alcohol and drug use (see Appendix A3). In addition, it examined 
exercise, smoking, and the presence of neurological or psychological disorders.  
Procedure                                                         
2 Although salivary samples were obtained, they are yet to be analysed as it is not 
within the scope of the study. 
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Ethics approval was obtained from the Tasmanian Social Sciences Human 
Research Ethics Committee (see Appendix B1). On arrival, participants were given a 
participant information sheet (see Appendix B2) and informed consent was obtained 
(see Appendix B3). Baseline saliva samples were taken using Salimetrics saliva 
collection tubes using a standardized passive drool method. Participants were then 
given the DASS-21, DERS and CCQ-M questionnaires to complete (see Appendix 
A). The US electrode was attached to the participant, and the participant determined 
the intensity of the shock, by administering the lowest level (2mA) and increasing 
the intensity until the participant reported the shock to be uncomfortable but not 
painful. The skin conductance response recording disks were attached to the 
participant’s fingers. Participants were told to remain still throughout the experiment 
in order to minimise movement artefact responses in the recording of skin 
conductance responses. Following this, participants completed the fear conditioning 
and extinction task. There were three phases in this task:  habituation, acquisition, 
and extinction. In the habituation phase, eight coloured circles (four blue, four red) 
were presented in a randomised order with no shock administered (as shown in 
Figure 5 below). Before commencing the habituation phase, participants were 
informed that they were not to receive an electric shock. 
 
Figure 5. Session 1 of the differential conditioning and extinction paradigm. 
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In the acquisition phase, sixteen coloured circles (8 blue, 8 red) were 
presented in a randomised order. The US was administered immediately after the 
CS+ was presented with a 62.5% partial reinforcement schedule (5 out 8 of the CS+ 
was paired with the US), in order to prevent rapid habituation to the CS+ during the 
acquisition phase. The extinction phase, which was divided into an early and a late 
sub-phase followed the acquisition phase. In each extinction sub-phase, ten coloured 
circles (5 blue, 5 red) were presented in a randomised order with no shock 
administered. Before commencing the acquisition and extinction phase, participants 
were informed that they ‘may or may not be administered with an electric shock’.  
Following the completion of the experiment, participants completed a 
questionnaire that examined whether they had understood CS+/US contingency.  
For the delayed recall measure, a second testing session was conducted 24 
hours following the initial session. In this session, SCR recording disks and the US 
electrode were attached to the participant’s hand and they completed the extinction 
phase of the task a second time (see Figure 6 below). SCR was recorded as per 
session 1. Participants were debriefed after the completion of the experiment. 
 
Figure 6. Session 2 of the differential conditioning and extinction paradigm. 
Analysis 
The SCR amplitude for each CS trial was indicative of the change from skin 
conductance level (SCL) baseline due to the presentation of the CS. Each CS was 
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displayed for 12 seconds, with an inter-trial interval ranging from 12 seconds to 21 
seconds (mean of 16 seconds). Skin conductance levels were indexed 2 seconds prior 
to the display of the CS, 12 seconds while the CS was displayed and also 6 seconds 
after the US was administered. Baseline SCL for each participant was calculated by 
averaging the SCL amplitude 2 seconds prior to the CS presentation in the 
Habituation phase. SCR amplitude was calculated by obtaining the highest skin 
conductance level (SCL) during the 12 second CS presentation and subtracting the 
mean SCL of the 2 seconds prior to the presentation of the CS. The SCR amplitude 
was indicative of the change from the baseline SCL following the CS presentation. 
In order to reduce reduce heteroscedasticity, the SCR data was square-root 
transformed (Milad et al., 2010).  
Data analysis for the fear acquisition and extinction study was conducted 
using 2 (Group: male, early follicular women) x 2 (CS: CS+, CS-) x  (Trial: 1, 2, 3, 
4) mixed factorial ANOVA in the Habituation phase, 2 (Group: male, early follicular 
women) x 2 (CS: CS+, CS-) x 5 (Trial: 1, 2, 3, 4, 5) mixed factorial ANOVA in the 
Acquisition phase, 2 (Group: male, early follicular women) x 2 (CS: CS+, CS-) x 5 
(Trial: 1, 2, 3, 4, 5) mixed factorial ANOVA in the Early Extinction and Late 
Extinction phase. For the Early and Late Recall phase, a percent recovery of fear 
value was calculated in order to control for the effect of conditioning (Graham & 
Milad, 2013). In this measure, the average SCR for each participant in the early and 
late recall phase were divided by their largest SCR to the CS+ in the acquisition 
phase. This was then multiplied by 100 to obtain the percent recovery of fear. A one-
way ANOVA was used to compare percent recovery of fear in the Early and Late 
Extinction Recall phase.  
Results 
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Demographic and Clinical data 
 A summary of demographic and clinical data is presented in Table 1. As 
shown in Table 1, males and females did not differ significantly with respect to age, 
body mass index (BMI), hours since awakening, quality of sleep, or time of day of 
the experiment. There were no significant differences between males and females on 
their subjective ratings of depression, anxiety and stress, as measured by the DASS-
21. Additionally, there were no significant differences between males and females in 
their ability to regulate their emotions, as measured by the DERS. There was no 
significant difference between males and females on the level of shock intensity 
selected. 
 
Table 1 
Means, Standard Deviations and F-tests for males and females for demographics 
 Males M (SD) Females M (SD) F p ηp2 
Age 24.92 years 
(6.10) 
25.53 years 
(6.89) 
0.06 .810 .002 
BMI 21.67 (2.42) 20.80 (2.98) 0.66 .423 .026 
Hours since 
wakening 
6.25 (3.14) 7.07 (2.63) 0.54 .469 .021 
Quality of sleep 6.83 (2.12) 6.60 (2.44) 0.07 .796 .003 
Time of 
experiment 
14:30 (2:35) 14:31 (2:07) 0.00 .998 <.001 
DASS-21 
Depression 
3.75 (4.88) 3.13 (3.02) 0.16 .690 .006 
DASS-21 Anxiety 3.33 (5.42) 3.87 (3.54) 0.10 .760 .004 
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DASS-21 Stress 4.83 (3.97) 5.87 (3.20) 0.56 .461 .022 
DERS 139.63 (177.44) 90.00 (20.24) 1.17 .291 .045 
Shock intensity 2.06 (0.22) 1.80 (0.53) 2.50 .126 .091 
Baseline SCL 8.21 (4.70) 7.05 (4.44) 0.43 .571 .017 
Note: M = Mean, SD = Standard Deviation 
Skin Conductance  
Baseline Skin Conductance. As shown in Table 1, there was no significant 
difference between males’ and females’ baseline SCL. 
Habituation. A 2 (Sex: Male, Female) x 2 (Condition:  CS+, CS-) x 4 (Trial: 
1, 2, 3, 4) mixed factorial ANOVA found that the main effects of Condition (F(1, 
25) = 0.09, p = .772, ηp2 = .003) and Sex (F(1, 25) = 2.63, p = .118, ηp2 = .095) 
were not significant. The main effect of Trial was significant, F(3,75) = 10.06, p < 
.001, ηp2 = .287. Sidak-adjusted pairwise comparisons revealed that there was a 
significant reduction in SCR from Trial 1 (M = .76) to Trial 4 (M = .53, p < .001, 
95% CI [0.10, 0.37]). The main effect of Trial was moderated by a significant Sex 
and Trial interaction, F(3, 75) = 3.56, p = .018, ηp2 = .125 (see Figure 7). Sidak-
adjusted pairwise comparisons broken down by Sex found that males’ mean SCR 
was significantly higher than females’ at Trial 2 (p = .043, 95% CI [0.01, 0.45]) and 
at Trial 3 (p = .042, 95% CI [0.01, 0.49]), but not at Trial 1 (p = .239, 95% CI [-0.09, 
0.33]) and Trial 4 (p = .805, 95% CI [-0.23, 0.18]). Sidak-adjusted pairwise 
comparisons broken down by Trial revealed that males’ SCR was not significantly 
higher from Trial 1 (M = .82) to Trial 2 (M = .77, p = .972, 95% CI [-0.13, 0.23]), 
Trial 2 to Trial 3 (M = .69, p = .663, 95% CI [-0.09, 0.26]) and Trial 3 to Trial 4 (M 
= .52, p = .268, 95% CI [-0.07, -0.41]). In contrast, females’ SCR was trending 
higher from Trial 1 (M = .70) to Trial 2 (M = .55, p = .066, 95% CI [-0.01, 0.32]), 
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but not significantly different at Trial 2 to Trial 3 (M = .44, p = .312, 95% CI [-0.05, 
0.26]), and Trial 3 to Trial 4 (M = .54, p = .707, 95% CI [-0.11, 0.31]). The three-
way interaction between Sex, Trial, and Condition was non-significant, F(3,75) = 
0.36, p = .785, ηp2 = .019. Additionally, the interactions between Sex and Condition, 
and Trial and Condition were not significant (p > .05, see Table C1 in Appendix C 
for details of non-significant interactions). 
Acquisition. A 2 (Sex: Male, Female) x 2 (Condition:  CS+, CS-) x 5 (Trial: 
1, 2, 3, 4, 5) mixed factorial ANOVA found a significant main effect of Condition, 
F(1, 25) = 4.89, p = .036, ηp2 = .164, indicating that overall, participants’ SCR to the 
CS+ (M = .78) was significantly higher than the participants’ SCR to the CS- (M = 
.66). There was a main effect at trend level for Trial, F(4, 100) = 2.42, p = .054, ηp2 
= .088 (see Figure 7). Sidak-adjusted pairwise comparisons demonstrated that Trial 1 
(M = .76) was trending higher than Trial 2 (M = .59, p = .060, 95% CI [0.00, 0.34]). 
Trial 2 was significantly lower than Trial 3 (M = .76, p = .015, 95% CI [-0.31, -
0.02]). Trial 3 was not significantly different to Trial 4 (M = .72, p = 1.000, 95% CI 
[-0.16, 0.23]), and Trial 4 was not significantly different to Trial 5 (M = .75, p = 
1.000, 95% CI [-0.21, 0.15]). The main effect of Sex was non-significant, F(1, 25) = 
0.41, p = .530, ηp2 = .016. The three-way interaction between Sex, Trial, and 
Condition was non-significant, F(4,100) = 1.30, p = .274, ηp2 = .050. Additionally, 
the interactions between Sex and Condition, Sex and Trial, and Trial and Condition 
were not significant and therefore were not explored further (see Table C2 in 
Appendix C for details of non-significant interactions). 
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Figure 7. SCR for males and females for each CS in the habituation, acquisition, early extinction, and late extinction phase. Error bars indicate 
standard errors. 
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Early Extinction. A 2 (Sex: Male, female) x 2 (Condition: CS+, CS-) x 5 
(Trial: 1, 2, 3, 4, 5) mixed factorial ANOVA found a significant main effect of Trial, 
F(4,100) = 7.75, p < .001, ηp2 = .237 (see Figure 7). Sidak-adjusted pairwise 
comparisons demonstrated that participants’ SCR was significantly higher from Trial 
2 (M = .72) to Trial 3 (M = .50, p = .005, 95% CI [.05, .39]), but was not 
significantly different from Trial 1 (M = .80) to Trial 2 (p = .963, 95% CI [-.13, 
.27]), Trial 3 to Trial 4 (M = .60, p = .809, 95% CI [-.30, .11]), or Trial 4 to Trial 5 
(M = .56, p = .998, 95% CI [-.14, .22]). There was no significant main effect of Sex 
(F(1, 25) = 0.13, p = .772, ηp2 = .005)  or Condition (F(1, 25) = 3.14, p = .089, ηp2 
= .112). 
 
 
Note: Error bars are 95% confidence intervals. 
Figure 8. SCR for CS+ and CS- condition for males and females in the early 
extinction phase. 
  
The interaction between Sex and Condition was significant, F(1,25) = 4.83, p 
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than females’ mean SCR in the CS- condition (M = .49, p = .011, 95% CI [.07, .47]) 
but was not significantly higher in the CS+ condition (p = .593, 95% CI [-.17, .29]). 
Sidak-adjusted pairwise comparisons broken down by Condition found that males’ 
mean SCR was not significantly different between conditions (p = .227, 95% CI [-
.24, .06]). Female’s mean SCR was significantly higher at trend level in the CS+ 
condition than the CS- condition (p = .067, 95% CI [-.01, .25]). The interaction 
between Sex and Trial (F(4, 100) = .44, p = .780, ηp2 = .017) and Trial and 
Condition (F(4, 100) = 0.37, p = .833, ηp2 = .014) were not significant and therefore 
not explored further. 
The three-way interaction between Sex, Trial, and Condition was significant, 
F(4,100) = 2.99, p = .022, ηp2 = .107. Break-down two-way ANOVAs for the Sex 
by Condition interaction for Trial 1 did not find a significant Condition effect or Sex 
effect (see Table C3 in Appendix C) but did find a significant Sex by Condition 
interaction (F(1,25) = 9.47, p = .005, ηp2 = .275). As can be seen in the early 
extinction phase panel of Figure 7, post-hoc pairwise comparisons found no 
significant sex differences to CS+ at Trial 1 (p = .520, 95% CI [-.49, .25]) but found 
that males’ SCR was greater than females to CS- on Trial 1 (p = .005, 95% CI [.17, 
.85]). Break-down two-way ANOVAs for Trial 2, Trial 3, Trial 4 and Trial 5 found 
no significant Condition effect, Sex effect, or Condition by Sex effects (see Table C3 
in Appendix C).  
Break-down two-way ANOVAs for the Sex by Trial interaction in the CS+ 
condition revealed no significant Sex effect (F(1, 25) = 0.29, p = .593, ηp2 = .012), 
and no significant  Sex by Trial effect (F(4, 100) = 1.46, p = .221, ηp2 = .055).  
There was a significant Trial effect (F(4,100) = 4.94, p = .001, ηp2 = .164) in the 
CS+ condition, with Sidak-adjusted pairwise comparisons indicating that 
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participants’ SCR significant dropped from Trial 2 (M = .73) to Trial 3 (M = .48, p < 
.001, 95% CI [.11, .39]), but was not significantly different from Trial 1 (M = .80) to 
Trial 2 (p = .996, 95% CI [-.17, .30]), Trial 3 to Trial 4 (M = .61, p = .716, 95% CI [-
.36, .11]), or Trial 4 to Trial 5 (M = .60, p > .999, 95% CI [-.25, .26]). Break-down 
two-way ANOVAs for the Sex by Trial interaction in the CS- condition found a 
significant Sex effect, with males’ SCR being higher than females (F(1,25) = 7.53, p 
= .011, ηp2 = .231). There was no significant Sex by Trial effect (F(1, 5) = .92, p = 
.348, ηp2 = .035).  A significant Trial effect was also observed in the CS- condition 
(F(4,100) = 4.39, p = .003, ηp2 = .146), with Sidak-adjusted pairwise comparisons 
demonstrating that Trial 1 (M = .80) was significantly higher than Trial 3 (M = .52, p 
= .018, 95% CI [.03, .52]), and Trial 1 was significantly higher than Trial 5 (M = .51, 
p = .001, 95% CI [.09, .48]). There were no significant differences between Trial 1 
and Trial 2 (M = .72, p = .995, 95% CI [-.21, .37]), Trial 2 to Trial 3 (p = .316, 95% 
CI [-.08, .47), Trial 3 to Trial 4 (M = .39, p = .996, 95% CI [-.33, .19]), or Trial 4 to 
Trial 5 (p = .990, 95% CI [-.19, .34]).  
Break-down two-way ANOVAs for the Condition by Trial interaction for 
females did not find a significant effect of condition, but found a significant Trial 
effect (F(4,56) = 5.60, p = .001, ηp2 = .286). The significant Trial effect was 
subsumed by a trend in the Trial by Condition effect (F(4,56) = .069, ηp2 = .141). 
Post-hoc pairwise comparisons found that in Trial 1, females’ SCR was trending 
higher for the CS+ condition than CS- condition (p = .057, 95% CI [-.01, .64]). 
Females’ SCR was also significantly higher in the CS+ condition at Trial 5 (p = 
.028, 95% CI [.03, .43]). There were no significant differences between conditions in 
Trial 2, Trial 3, or Trial 4 (see Table C4 in Appendix C). 
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Break-down two-way ANOVAs for the Condition by Trial interaction for 
males did not find a significant Condition effect (F(1, 11) = 1.98, p = .187, ηp2 = 
.153) or Condition by Trial effect (F(4, 44) = 1. 22, p = .317, ηp2 = .100). There was 
a significant Trial effect, F(4,44) = 3.02, p = .028, ηp2 = .215. Post-hoc pairwise 
comparisons indicated that SCR trended higher at Trial 1 (M = .89) compared to 
Trial 5 (M = .60, p = .085, 95% CI [-.03, .61]). There were no significant differences 
observed between Trial 1 and Trial 2 (M = .78, p = .952, 95% CI [-.22, .44]), Trial 2 
and Trial 3 (M = .59, p = .294, 95% CI [-.09, .47]), Trial 3 and Trial 4 (M = .72, p = 
.977, 95% CI [-.55, .30]) or Trial 4 to Trial 5 (p = .967, 95% CI [-.24, .47]). 
Late Extinction. A 2 (Sex: Male, Female) x 2 (Condition: CS+, CS-) x 5 
(Trial: 1, 2, 3, 4, 5) mixed factorial ANOVA found no significant main effect of Sex 
(F(1, 25) = 1.92, p = .178, ηp2 = .071), Trial (F(2.29, 57.36) = 0.65, p = .544, ηp2 = 
.025) following a greenhouse geisser correction, or Condition (F(1, 25) = 0.02, p = 
.882, ηp2 = .001) (see Figure 7). All other interaction effects were non-significant (p 
> .05, see Table C5 in Appendix C for details of non-significant interactions). 
Extinction Recall Early. Extinction recall data for the early extinction recall 
phase was calculated by obtaining a percent recovery of fear, which controls for the 
conditioning effect . This was calculated by obtaining an average SCR to the CS+ 
for each participant in the early recall phase which was divided by each participant’s 
largest SCR to the CS+ in the acquisition phase, as according to Graham and Milad 
(2013). This value was then multiplied by 100 to obtain the percent recovery of fear. 
A one-way ANOVA found no significant differences in the percent recovery of fear 
in males (M = 54.43) and females (M = 70.14) in the early recall phase for CS+, F(1, 
25) = 1.51, p = 230, ηp2 = .057 (see Figure 9). 
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Note: Error bars are 95% confidence intervals. 
Figure 9. Percent fear recovery in the early recall phase for CS+ in males and 
females. 
 
Extinction Recall Late. A percent recovery of fear value was also obtained 
for the late extinction recall phase, whereby an average SCR to the CS+ for each 
participant in the late recall phase was divided by each participant’s largest SCR to 
the CS+ in the acquisition phase. This value was then multiplied by 100. A one-way 
ANOVA found a trend towards significance with females demonstrating a higher 
percent recovery of fear (M = 73.66) than males (M = 48.88, F(1,25) = 3.29, p = 
.082, ηp2 = .116) (see Figure 10).  
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Note: Error bars are 95% confidence intervals. 
Figure 10. Percent fear recovery in the late phase for CS+ in males and females.  
 
Discussion 
The aim of the current study was to replicate the findings of low oestrogen 
levels being associated with impaired fear extinction (Graham & Milad, 2013) by 
comparing SCR during fear conditioning, fear extinction, and extinction recall in 
women in the low oestrogen, early follicular phase of the menstrual cycle compared 
to men. Results revealed no significant sex differences across trial or condition in 
fear acquisition. In the early extinction phase, males displayed greater SCR in initial 
trials to the CS- than females. There were no significant sex differences obtained in 
the percent recovery of fear to the CS+ in the early recall phase as predicted, but a 
trend was found in the late recall phase that females displayed a greater recovery of 
fear relative to men. These findings provide some support that females with low 
oestrogen display reduced fear extinction retention compared to males, but also 
suggest that males display enhanced reactivity to safety signals during extinction, 
which may reflect a generalized arousal or response to uncertainty.   
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Sex Differences in Fear Conditioning and Fear Extinction 
Habituation. There were no differences in SCR to the CS+ and CS- in the 
habituation phase. This was expected, as the participants had not yet learnt the 
association between specific stimuli and the shock. There was main effect of Trial, 
suggesting that participants had habituated to the stimuli. This main effect was 
moderated by a Sex by Trial interaction, which demonstrated that male’s SCR were 
higher than females at only Trial 2 and Trial 3, and not Trial 1 or Trial 4. In addition, 
female’s SCR trended higher only from Trial 1 to Trial 2. However, this interaction 
does not appear to be meaningful, and it is possible that these observations are best 
explained by the participant’s uncertainty about receiving or not receiving a shock. 
Acquisition. As expected, there was a significant Condition effect during the 
acquisition phase with participants exhibiting a greater SCR to the CS+ relative to 
the CS-. This suggests that fear conditioning successfully occurred, as differential 
responses to the stimuli were observed in the acquisition phase. There was a trend 
effect of Trial, with Trial 1 trending higher than Trial 2, Trial 2 being significantly 
lower than Trial 3, but no differences between Trial 3 to Trial 4, or Trial 4 or Trial 5. 
In addition, there was no significant interaction between Condition and Trial, which 
suggests that differential responses to the stimuli did not significantly increase across 
trials. The non-significant interaction may be attributed to a 62.5% reinforcement 
rate, as participants were shocked five out of eight times in the acquisition phase, in 
a random order. As such, participants may have heightened uncertainty about 
whether they would be shocked with the next stimuli, and as such, display high 
levels of SCR with each presentation of each stimuli.  
Due to inconsistent evidence in sex differences in the fear acquisition phase, 
a directional hypothesis was not predicted. There was no main effect of Sex, or any 
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interaction effects observed in the fear acquisition phase, which indicates that there 
were no differences between males and females in their SCR. Previous research in 
fear conditioning in humans have found that males are more reactive than women 
during the acquisition phase, i.e., males display greater SCR than females during 
acquisition (Milad et al., 2006; Milad et al., 2010). However, a study conducted by 
Zeidan et al. (2011) found no sex differences in the acquisition phase, which is 
consistent to the findings of our study. A possible explanation for the differences 
between the SCR in males and females could be the reinforcement rate, as Milad et 
al. (2006) and Milad et al. (2010) utilised a 100% reinforcement rate, whereas 
Zeidan et al. (2011) used a 62.5% reinforcement rate, which was also used in the 
current study. 
Extinction. Any Sex or Condition or Trial effects or interactions were 
observed in the early rather than the late extinction phase. In the early extinction 
phase, there was a significant Trial effect, indicating that participant’s SCR reduced 
across trials. Further, there was no significant condition main effect, suggesting there 
was no differential SCR to the CS+ and CS- stimuli during early extinction. Taken 
together, these effects suggest that fear extinction learning has taken place, as there 
is no longer a discrimination between CS+ and CS-. A Condition by Trial interaction 
would be the strongest evidence of extinction learning, but this interaction was not 
observed in the study. However, there was a significant Sex by Condition by Trial 
interaction effect observed. It was hypothesised that women in the early follicular 
phase of their menstrual cycle would display impaired fear extinction in comparison 
to men, which is reflected in higher levels of SCR to the CS+.  
The significant three way interaction (Sex by Condition by Trial interaction) 
found in the early extinction phase revealed an interesting pattern of sex differences.  
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In line with hypotheses, there was a trend for a Condition by Trial effect in women, 
but not in men. Pairwise analyses revealed that in women, there was a trend for 
greater SCR to CS+ compared to CS- on the initial trial of extinction, and this 
difference became significant at Trial 5 of extinction. In contrast, there was no 
significant Condition by Trial interaction effect in men. Whilst this must be 
interpreted cautiously as it is only at trend level and a small effect size, this finding is 
in line with predictions as it suggests that women continue to react more to the CS+ 
compared to CS- across fear extinction, whereas men do not. However, there were 
no overall sex differences in response to CS+ conditions, which again suggests 
caution in interpretation. This trend level finding and lack of overall sex differences 
accords with growing evidence that sex differences (and particularly effect of low 
oestrogen) is not as evident in fear extinction learning but is more prevalent in fear 
extinction recall which involves memory consolidation processes (Milad et al., 2006; 
Milad et al., 2010; Zeidan et al., 2011). 
An unexpected sex difference was observed within the significant three-way 
interaction in the early extinction phase. Pairwise comparisons revealed that males’ 
SCR was higher than females’ SCR to CS- (with no sex differences to CS+) on Trial 
1 and this pattern was at trend level for Trial 4. It is possible that females had learnt 
that the CS- was a safety signal and had remembered this in the extinction phase, 
whereas males may have demonstrated greater uncertainty across conditions. This is 
an interesting finding, as this finding suggests that females show less fear responding 
to safety signal, whereas males show more fear responding and possibly more 
uncertainty to a safety signal.  
Sex Differences in Extinction Recall 
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 The results of this study partially supported that hypothesis that women in the 
early follicular phase would display impaired fear extinction recall relative to men, 
which would be reflected by a greater recovery of fear. In the early extinction recall 
phase, we did not find any significant sex differences between the percent recovery 
of fear to the CS+, however we found a trend for a sex difference in the extinction 
late recall phase (ηp2 = .116). Interestingly, when examining Figure 9 and Figure 10, 
mean differences were in the expected direction that women in the early follicular 
phase exhibited a greater recovery of fear, relative to men (70.14% vs 54.43% in 
early recall, 73.66% vs 48.88% for late), albeit not reaching significance. These 
results provided partial support for our hypotheses and for findings obtained by 
previous studies (Graham and Milad (2013), Milad et al. (2010) and Zeidan et al. 
(2011)), where females with low levels of oestrogen displayed impaired fear 
extinction at recall, relative to males, and females with high levels of oestrogen. 
Similar findings with oestrogen playing an important role in the facilitation of 
extinction memory have also been demonstrated in rat studies, with female rats in 
the metestrus phase, characterised by low levels of oestrogen, demonstrated impaired 
fear extinction recall, relative to male rats, and female rats with high oestrogen levels 
(Milad et al., 2009). It is possible that we did not find a significant difference 
between females in the early follicular phase and males in support of the previous 
studies (Graham & Milad, 2013; Milad et al., 2010; Zeidan et al., 2011), due to a 
limited sample size, which led to poor power. In addition, we included women on 
oral contraceptives due to considerable difficulty with participant recruitment (data 
was collected for over a 12 month period). The inclusion of women on 
contraceptives may have also reduced the effect size obtained in the study.  
Limitations and Future Research 
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Despite the contribution of the present study to the area of fear conditioning 
and extinction, the present study has a number of potential limitations. One of the 
key limitations of the present study is the small sample size, which led to this study 
being considerably underpowered. This may be attributed to the difficulty in the 
recruitment of participants, especially as there were several requirements that the 
participant needed to meet in order to participate, e.g., age restrictions, no 
contraception in women other than the contraception pill, and no psychological, 
neurological or cardiovascular disease.  
The difficulty in recruitment also limited the scope of the study, as females 
were only tested in the early follicular phase of the menstrual cycle, where oestrogen 
levels are typically low. The original aim of this project was to recruit and test 
women in both the low oestrogen (early follicular) and high oestrogen (late 
follicular) phases of the menstrual cycle, which would have provided a more direct 
and definitive test of the impact of oestrogen on fear extinction. In order to replicate 
the findings obtained from previous studies examining the sex differences in fear 
extinction recall, conducted by Graham and Milad (2013), Milad et al. (2010), and 
Zeidan et al. (2011), future research should endeavour to investigate other phases of 
the menstrual cycle, such as the late follicular phase, where oestrogen levels are 
high.  
In addition, whilst all women were tested within 1-7 days of commencing 
menstruation, thus ensuring they were in the early follicular phase, oestrogen levels 
in participants in the current study were not confirmed with salivary samples3. It is 
recommended that for future studies, confirmation of oestrogen levels should be 
included, especially when examining other phases of the menstrual cycle.                                                         
3 Salivary samples were obtained, however not analysed as it was not within the 
scope of the thesis. 
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A further limitation was the inclusion of women on oral contraception in the 
study, necessitated due to participant recruitment difficulties. The initial recruitment 
of women not on contraception was attempted over a period of seven months, but 
proved too difficult and necessitated including women in the sugar pill phase of the 
contraceptive pill. In addition, research has also indicated that women on the sugar 
pill phase of the contraceptive pill have comparative levels of extinction recall 
relative to women in the early follicular phase of their menstrual cycle (Graham & 
Milad, 2013). In the current study, females in the early follicular phases consisted of 
females who did and did not take oral contraceptives (8 females without oral 
contraceptives and 7 females on oral contraceptives), which previous research has 
indicated that both groups demonstrate similar levels of oestrogen (Pluchino et al., 
2009). Unfortunately, we did not have sufficient numbers of participants to compare 
females with and without contraception statistically. However, it may be helpful for 
future research to explore the impact of oral contraceptives and other forms of 
contraception, such as implants or intrauterine devices, on fear conditioning and fear 
extinction. This is particularly important as approximately 45% of women aged 
between 18 and 44 use some form of contraception in Australia (Gray & McDonald, 
2010).  
To date, no studies have examined fear conditioning and fear extinction 
across the different phases of the menstrual cycle in females, by utilising a within-
subjects design. This may allow a more nuanced understanding of differences in fear 
conditioning and fear extinction with variations in sex hormones, as the luteal phases 
are associated with high progesterone and high oestrogen (mid luteal phase), and 
high progesterone and low oestrogen (late luteal phase), and the effects of oestrogen 
on extinction recall may vary in the context of high and low progesterone (Wegerer, 
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Kerschbaum, Blechert, & Wilhelm, 2014). However, a potential barrier to this would 
be the challenge of identifying valid ways of repeated testing of fear extinction recall 
in a within subjects design.  
Theoretical and Clinical Implications 
 Although the current study has important limitations that must qualify 
conclusions, they do support a growing body of research that has potentially 
important clinical implications. Various epidemiological studies have consistently 
demonstrated that women are more likely to have an anxiety disorder than men 
(Kessler et al., 2005; Kinrys & Wygant, 2005; Pigott, 2003). In addition, studies 
have also indicated periods in which oestrogen exists at low levels, such as 
premenstrual and postpartum periods, are associated with a worsening of symptoms 
and mental state (Douma et al., 2005; Östlund, Keller, & Hurd, 2003). It is possible 
that the findings of the current study may influence the treatment of individuals with 
anxiety disorders, so that exposure treatment (which is based on the principles of 
extinction learning) is focused on periods where women demonstrate higher levels of 
oestrogen, i.e., during the late follicular phase or mid-luteal phase, to facilitate 
extinction learning. Additionally, given that periods in which low levels of 
oestrogen, i.e., the early follicular phase, are associated with poor extinction memory 
recall, it is possible that treatment of anxiety disorders may be facilitated by 
providing individuals with an endogenous administration of oestrogen prior to 
extinction training. Initial evidence in support of this hypothesis is seen in a study 
conducted by Graham and Milad (2013) where women in the early follicular phase 
were administered oestrogen 30 minutes prior to extinction and displayed enhanced 
extinction recall, relative to women given a placebo. These promising results with 
oestrogen may be trialled in the future with individuals undergoing anxiety 
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treatment, to determine whether these results are obtained in a clinical setting. It is 
possible that treatment for anxiety disorders could also be successfully obtained with 
fewer sessions as well, if it is found that oestrogen facilitates extinction recall. 
Conclusion 
The aim of the current study was to replicate the findings obtained by 
previous authors, by investigating sex differences in fear conditioning, fear 
extinction, and extinction recall, in particular in women with low levels of oestrogen. 
No sex differences were observed in fear acquisition or late extinction, but males 
displayed greater SCR to the CS- in early extinction, which may reflect greater 
arousal to uncertainty. There was a trend for females to continue to have greater SCR 
to the CS+ compared to the CS- throughout early extinction, which was not apparent 
in males. In addition, females displayed a trend for greater SCR responses during 
extinction recall compared to men. Although there were significant limitations in 
terms of power, sample size and composition, the findings of the current study 
provide partial support for previous studies that have found poor extinction recall in 
women with low levels of oestrogen. It is possible that oestrogen may have an 
important role in consolidating extinction memories, however further research is 
required with larger samples, and examining all menstrual phases in addition to the 
impact of oral contraceptives, to investigate the role of oestrogen in facilitating 
extinction recall. 
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Appendix A1 
Depression, Anxiety and Stress Scale 
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Appendix A2 
Difficulties in Emotion Regulation Scale 
 
Please indicate how often the following statements apply to you by writing the 
appropriate number from the scale below on the line beside each item:  
___________________________________________________________________ 
 
 1-----------------------2-----------------------3-----------------------4-----------------------5        
almost never       sometimes         about half the time       most of the time       almost always        
(0-10%)              (11-35%)                 (36-65%)                    (66-90%)                 (91-100%)  
____________________________________________________________________ 
______    1) I am clear about my feelings. 
______    2) I pay attention to how I feel.  
______    3) I experience my emotions as overwhelming and out of control.  
______    4) I have no idea how I am feeling.  
______    5) I have difficulty making sense out of my feelings.  
______    6) I am attentive to my feelings. 
______    7) I know exactly how I am feeling.  
______    8) I care about what I am feeling.  
______    9) I am confused about how I feel. 
______    10) When I’m upset, I acknowledge my emotions. 
______    11) When I’m upset, I become angry with myself for feeling that way.  
______    12) When I’m upset, I become embarrassed for feeling that way.  
______    13) When I’m upset, I have difficulty getting work done.  
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___________________________________________________________________ 
 
 1-----------------------2-----------------------3-----------------------4-----------------------5        
almost never       sometimes         about half the time       most of the time       almost always        
(0-10%)              (11-35%)                 (36-65%)                    (66-90%)                 (91-100%)  
____________________________________________________________________ 
______    14) When I’m upset, I become out of control.  
______    15) When I’m upset, I believe that I will remain that way for a long time.  
______    16) When I’m upset, I believe that I’ll end up feeling very depressed.  
______    17) When I’m upset, I believe that my feelings are valid and important. 
______    18) When I’m upset, I have difficulty focusing on other things. 
______    19) When I’m upset, I feel out of control.  
______    20) When I’m upset, I can still get things done.  
______    21) When I’m upset, I feel ashamed with myself for feeling that way. 
______    22) When I’m upset, I know that I can find a way to eventually feel better. 
______    23) When I’m upset, I feel like I am weak.  
______    24) When I’m upset, I feel like I can remain in control of my behaviors. 
______    25) When I’m upset, I feel guilty for feeling that way. 
______    26) When I’m upset, I have difficulty concentrating.  
______    27) When I’m upset, I have difficulty controlling my behaviors.  
______    28) When I’m upset, I believe that there is nothing I can do to make myself 
feel better.  
______    29) When I’m upset, I become irritated with myself for feeling that way. 
______    30) When I’m upset, I start to feel very bad about myself. 
______    31) When I’m upset, I believe that wallowing in it is all I can do. 
______    32) When I’m upset, I lose control over my behaviors.  
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___________________________________________________________________ 
 
 1-----------------------2-----------------------3-----------------------4-----------------------5        
almost never       sometimes         about half the time       most of the time       almost always        
(0-10%)              (11-35%)                 (36-65%)                    (66-90%)                 (91-100%)  
____________________________________________________________________ 
______    33) When I’m upset, I have difficulty thinking about anything else.  
______    34) When I’m upset, I take time to figure out what I’m really feeling. 
______    35) When I’m upset, it takes me a long time to feel better.  
______    36) When I’m upset, my emotions feel overwhelming.  
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Appendix A3 
Health Questionnaire 
Health Questionnaire: 
1. Are you taking medications?  What and what dose? 
_________________________________________________________ 
2. How many drinks of caffeine did you have yesterday? 
_________________________________________________________ 
3. What time was your last drink of caffeine yesterday?  
_________________________________________________________ 
4. How much exercise do you typically do each day? 
_________________________________________________________ 
5. How many minutes of exercise did you do yesterday?  
_________________________________________________________ 
6. When did you do finish your exercise yesterday? 
__________________________________________________________ 
7. How many cigarettes did you smoke yesterday?     
__________________________________________________________ 
8. When was the last cigarette that you smoked yesterday? 
__________________________________________________________ 
9. How many alcoholic drinks did you have yesterday?  
__________________________________________________________ 
10. At what time was your last alcoholic drink yesterday?  
__________________________________________________________ 
11. How many alcoholic drinks do you typically have each week? 
__________________________________________________________ 
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12. Have you ever had a head injury/loss of consciousness for more than 5 
minutes? 
YES/NO 
13. Do you have any other neurological disorders?  
(epilepsy/parkinsons/dementia)  
YES/NO 
a. If so, what and for how long have you had this? 
__________________________________________________ 
14. Have you any problems with your mental health (including an anxiety 
disorder or depression?)  If so, what problem and for how long? 
_________________________________________________________ 
15. Do you have any problems with your memory?  If yes. What? 
__________________________________________________________ 
 
 
 
 
  
 
49 
Appendix B1 
Tasmanian Social Sciences Human Research Ethics Committee Amendment 
Approval Letter 
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Appendix B2 Participant Information Sheet 
 
Participant Information Sheet 
  
Title:  Sex differences in fear extinction  
Date: 
 
Invitation 
You are invited to participate in a research study examining the influence of 
hormones on fear extinction.  This study will be carried out in the Cognitive 
Neuroscience (ERP) Laboratory at the School of Psychology, University of 
Tasmania (Hobart).  This study is being conducted by Annie To (Masters student), 
supervised by Professor Kim Felmingham in partial fulfilment of the requirements of 
their postgraduate studies in the School of Psychology, University of Tasmania. 
What is the purpose of this study? 
The purpose of this study is to investigate the influence of hormones on fear 
conditioning and extinction which are key processes thought to underlie the 
development and treatment of anxiety disorders.  Recent evidence reveals that 
cognitive variables and sex may influence the rates of fear conditioning and 
extinction, but few studies have examined the influence of hormones. 
Why have I been invited to participate? 
You have been invited to participate as you are a psychology first year student and 
this project is being offered as part of research participation course credit.  We are 
looking for volunteers between the ages of 18 and 55, who are not currently taking 
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any medication, and who have no history of psychiatric disorders. We will ask you 
to complete a questionnaire about these conditions before the experiment begins.  
What will I be asked to do? 
You will be asked to come in for two testing sessions at the University of Tasmania, 
the first will take approximately 60 minutes and the second (24 hours later) will take 
approximately 30 minutes. The study will be run in the Cognitive Neuroscience 
Laboratory in the School of Psychology.  In the first session, you will be asked to sit 
in a quiet room and complete some questionnaires about your mood, beliefs and 
cognitive processing style. You will also be asked to fill in a medical history 
questionnaire, which will ask about the position that you are in your menstrual cycle 
and contraceptive use (if you are female). The study will also require taking saliva 
samples (collecting saliva in a small plastic tube).  The samples will be examined by 
laboratory technicians to measure your current levels of oestrogen, progesterone, 
noradrenaline and cortisol. You will then complete a behavioural task which 
examines how your body arousal (sweat gland activity) reacts to a mild electrical 
stimulus that will be administered to your fingertips. You will first be asked to select 
a level of mild electrical stimulus that feels uncomfortable but not painful to you. 
This will be done by attaching a finger stimulator to your index finger and delivering 
the lowest level of electrical stimulus, the level of which will then be increased in 
small increments until you report that it feels uncomfortable but not painful. You 
will then be asked to complete the behavioural task. In this task, you will sit in front 
of a computer screen and small recording disks will be attached to your finger tips to 
measure your body arousal (via skin conductance). You will then be asked to watch 
the computer screen on which you will see different coloured circles (red, or blue) 
appear. Following the presentation of some of these coloured circles, you will 
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receive an electrical stimulus which will be set at the level which you have 
previously chosen. You will also be asked to provide ratings on how much you are 
expecting to receive the electrical stimulus in the task.  The behavioural task will last 
approximately 15 minutes.  
In the second session, you will be asked to provide a second saliva sample and then 
complete one part of the behavioural task again.  This will involve having small 
recording disks and the finger stimulator to your fingers, and observing the coloured 
circles.  In this second testing session, you will not receive electric shocks. 
What will happen to my sample after it has been tested? 
Your saliva sample will only be used for the purpose of this research study.  The 
saliva samples you provide during the study will be destroyed at the completion of 
the study.  Your saliva samples will not be used for genetic testing or disease 
markers. 
Will I be able to get my sample back if I want? 
No, your saliva sample will be destroyed following laboratory analysis. 
Will drug or biotechnology companies be able to use my sample for profit in 
future? 
No. 
How is this study being paid for? 
The study is being sponsored by a grant from the National Health and Medical 
Research Council. 
Are there any possible benefits from participation in this study? 
If you decide to participate in this research you will gain experience in research 
procedures and also some knowledge of underlying mechanisms of anxiety and 
exposure therapy. If you are enrolled in first year Psychology, you will also receive 
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research participation credit of 1 hour for your participation. Furthermore, you will 
be involved in research that may provide a platform to better understand the 
mechanisms and processes involved in the extinction of fear, and this may ultimately 
lead to more efficient and effective exposure treatments for anxiety disorders. 
Are there any possible risks from participation in this study? 
Prior to commencement of the study you will be asked to sign consent form which 
will evidence your agreement to participate. You may feel a small amount of arousal 
or discomfort from the mild electrical stimulus. However, we expect that this arousal 
or discomfort to be minimal as the level that is administered will have been selected 
by you to be uncomfortable but not painful. The technology used to administer this 
electrical stimulus is very safe and has been used in many previous studies with no 
adverse effect reported. There will be a researcher with you at all times, and you can 
discontinue the study at any time without penalty and it will not affect your 
relationship with the University of Tasmania or the School of Psychology.   
What if I change my mind during or after the study? 
Participation in this research is entirely voluntary. You may choose to withdraw 
from the study at any time without prejudice. Deciding to withdraw from this 
research at any time will not affect your academic standing in any way. You can also 
choose at this time to withdraw any data previously collected. Participants will be 
given copies of this information sheet and the statement of informed consent.  
What will happen to the information when this study is over? 
Your individual data will be treated confidentially, your name will be replaced by an 
ID number on all data. It will be kept in a locked cabinet or on password secured 
computers at the School of Psychology at the University of Tasmania for a period of 
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at least five years (with the exception of the medical questionnaires which will be 
destroyed on completion of the study).  
How will the results of the study be published? 
Following completion of the research, the data will be published. However, no 
participant will be personally identifiable in these publications as only group data 
will be published. A summary of the results of these experiments will be available on 
the university of Tasmania School of Psychology Web page at 
www.scieng.utas.edu.au/psychol or will be available by contacting the researchers. 
What if I have questions about this study? 
The researchers will be available after the testing session to answer any questions 
you may have. If you have any questions, or would like any additional information 
regarding this research please contact, Annie To ato0@postoffice.utas.edu.au., or 
Prof Kim Felmingham at Kim.Felmingham@utas.edu.au. 
This study has been approved by the Tasmanian Social Sciences Human Research 
Ethics Committee. If you have concerns or complaints about the conduct of this 
study, please contact the Executive Officer of the HREC (Tasmania) Network on 
(03) 6226 7479 or email human.ethics@utas.edu.au. The Executive Officer is the 
person nominated to receive complaints from research participants. Please quote 
ethics reference number H0012496.  
 
 
Thank you for taking the time to consider this study. 
If you wish to take part in it, please sign the attached consent form. 
This information sheet is for you to keep. 
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Appendix B3 
Consent Form 
 
 Participant Consent Form  
 
Sex differences in fear extinction: The influence of cognitive variables. 
 
Participant Consent Statement: 
1. I agree to take part in the research study named above. 
2. I have read and understood the Information Sheet for this study. 
3. The nature and possible effects of the study have been explained to me. 
4. Any questions that I have asked have been answered to my satisfaction. 
5. I understand that the study requires me to attend the Cognitive Neuroscience 
laboratory at the School of Psychology where my arousal responses will be 
recorded whilst I view different coloured circles and receive a mild electrical 
stimulus to my fingers. I understand that I can set the level of this mild 
electrical stimulus to feel uncomfortable but not painful prior to the task. I 
understand I will be asked to provide a saliva sample to get estimates of 
estrogen and progesterone. I also understand that I will attend two sessions 
for this task – one will take approximately one hour and one two days later 
for 30 minutes. 
6. I understand that I will be asked about recreational drug habits, use of 
prescription medication and my menstrual cycle and contraceptive use (if 
female). I also understand that I should indicate to their experimenter if I 
have sensitive skin and that I should request a rest if I become fatigued.  
7. I understand that all research data will be treated as confidential. I agree that 
research data gathered for the study may be published provided that I cannot 
e identified as a participant.   
8. I understand that my participation is voluntary and that I may withdraw from 
participation and/or withdraw my data at any time without prejudice to my 
academic standing 
 
Participant’s name:  ________________________________________  
 
Participant’s signature: ______________________________________ 
 
Date:  ___________ 
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Investigator Statement 
 
I have explained this research and the implications of participation in it to this 
volunteer and I believe that the consent is informed and that she understands the 
implications of participation 
 
Investigator’s name:  ________________________________________  
 
Investigator’s signature: ______________________________________ 
 
Date: ___________ 
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Appendix C 
Table C1 
Non-significant Interactions for SCR in the Habituation Phase 
   Mean F df p ηp2 
Condition by sex Male CS+ .68 1.95 1, 25 .175 .072 
  CS- .72     
 Female CS+ .59     
  CS- .53     
Condition by trial CS+ Trial 1 .77 0.40 3, 75 .756 .016 
  Trial 2 .69     
  Trial 3 .55     
  Trial 4 .52     
 CS- Trial 1 .75     
  Trial 2 .63     
  Trial 3 .58     
  Trial 4 .53     
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Table C2 
Non-significant Interactions for SCR in the Acquisition Phase 
   Mean F df p ηp2 
Condition by sex Male CS+ .80 0.02 1, 25 .885 .001 
  CS- .69     
 Female CS+ .75     
  CS- .62     
Condition by trial CS+ Trial 1 .82 1.26 4, 100 .292 .048 
  Trial 2 .63     
  Trial 3 .83     
  Trial 4 .74     
  Trial 5 .88     
 CS- Trial 1 .70     
  Trial 2 .56     
  Trial 3 .69     
  Trial 4 .71     
  Trial 5 .62     
Trial by sex Male Trial 1 .73 0.84 4, 100 .504 .032 
  Trial 2 .63     
  Trial 3 .80     
  Trial 4 .74     
  Trial 5 .83     
 Female Trial 1 .79     
  Trial 2 .56     
  Trial 3 .72     
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  Trial 4 .70     
  Trial 5 .67     
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Table C3 
Summary of Breakdown two-way ANOVA for the Sex by Condition interaction at 
each Trial in the Early Extinction phase 
   Mean F df P ηp2 
Trial 1 Sex Male .89 1.97 1, 25 .173 .073 
  Female .70     
 Condition CS+ .80 0.00 1, 25 .998 0.00 
  CS- .80     
 Sex by Condition  9.47 1, 25 .005 .275 
Trial 2 Sex Male .78 .83 1, 25 .370 .032 
  Female .67     
 Condition CS+ .73 .02 1, 25 .883 .001 
  CS- .72     
 Sex by Condition  .19 1, 25 .663 .008 
Trial 3 Sex Male .59 2.98 1, 25 .097 .106 
  Female .41     
 Condition CS+ .48 .32 1, 25 .578 .013 
  CS- .52     
 Sex by Condition  .98 1, 25 .331 .038 
Trial 4 Sex Male .72 4.03 1, 25 .056 .139 
  Female .48     
 Condition CS+ .61 .06 1, 25 .809 .002 
  CS- .59     
 Sex by Condition  .42 1, 25 .525 .016 
Trial 5 Sex Male .60 .71 1, 25 .409 .027 
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  Female .51     
 Condition CS+ .60 1.35 1, 25 .257 .051 
  CS- .51     
 Sex by Condition  3.22 1, 25 .085 .114 
 
Table C4 
Summary of non-significant post-hoc pairwise comparisons for the Trial by 
Condition interaction for females in the Early Extinction phase 
  Mean p 95% CI 
Trial 2 CS+ .65 .832 [-.29, .23] 
 CS- .68   
Trial 3 CS+ .43 .746 [-.16, .21] 
 CS- .40   
Trial 4 CS+ .51 .386 [-.10, .23] 
 CS- .44   
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Table C5 
Non-significant Interactions for SCR in the Late Extinction Phase 
   Mean F df p ηp2 
Condition by sex Male CS+ .70 0.09 1, 25 .763 .004 
  CS- .69     
 Female CS+ .51     
  CS- .53     
Condition by trial CS+ Trial 1 .67 1.64 2.94, 
73.38 
.170 .062 
  Trial 2 .59     
  Trial 3 .62     
  Trial 4 .53     
  Trial 5 .60     
 CS- Trial 1 .66     
  Trial 2 .61     
  Trial 3 .52     
  Trial 4 .70     
  Trial 5 .55     
Trial by sex Male Trial 1 .80 0.89 2.29, 
57.36 
.474 .025 
  Trial 2 .70     
  Trial 3 .59     
  Trial 4 .71     
  Trial 5 .67     
 Female Trial 1 .53     
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  Trial 2 .49     
  Trial 3 .56     
  Trial 4 .53     
  Trial 5 .48     
Condition by Sex by Trial  0.67 2.94, 
73.38 
.617 .026 
 
 
 
 
